Focus: R-Pharm US is a specialty biotech company focused on acquiring and commercializing small-molecule products across cardiovascular, neurology, infectious diseases, oncology, and respiratory indications. The company operates as a product acquisition platform with a diversified portfolio generating ~$430M in annual revenue.
Profile data last refreshed 16h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow R-Pharm US to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for R-Pharm US
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from R-Pharm US's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship product representing 37% of company revenue; patent expiration in August 2026 is the most critical near-term event for the company.
Generic parathyroid hormone analog; post-exclusivity product generating steady revenue in osteoporosis market.
Branded ARB with patent protection through March 2028; represents second-tier revenue exposure to upcoming patent cliff.
Generic prostaglandin analog for glaucoma; established product with stable post-LOE revenue generation.
Extended-release gabapentin formulation with patent protection through June 2029; faces patent cliff within 4 years.
Bowel preparation agent with patent protection extending to August 2037; offers long-term revenue stability.
Branded combination antihypertensive with patent exclusivity through July 2031; provides intermediate-term revenue support.
Novel glucagon nasal powder formulation with long patent protection through September 2039; differentiated delivery in diabetes emergency care.
Generic thiazide diuretic; established post-LOE product with modest but stable revenue contribution.
615 discontinued, 173 duplicate formulations not shown
+18 more products with revenue data
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
+116 more products
Recent layoffs combined with zero open roles and imminent $181M revenue cliff from NUEDEXTA (August 2026) signal elevated organizational instability and further downsizing risk.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo